To date, CAR-NK cells have been administered to r/r CD19-positive cancer patients (CLL or NHL) and demonstrated a promising response rate (73%) with no major toxicity [197]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.